The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

When we think about the protection that can be provided by a comprehensive immunization plan, we think in terms of lifetimes. It’s vital that we also remember the important moments that make up each ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...